The 30-second summary
- Energy intake fell by 24% in a controlled feeding study, measured by weighing food rather than asking people to remember it.
- What you want changes, not just how much. Less hunger, fewer cravings, better control of eating, and a lower relative preference for fatty, energy-dense food.
- It is not just the slow stomach. Appetite and weight changes were not related to delayed gastric emptying or to side effects.
- Resting metabolic rate did not fall once adjusted for lean mass. The loss came from the intake side.
- Protein falls with everything else, and nothing in the experience tells you it has.
The study that measured it properly
Most of what is claimed about appetite comes from questionnaires. One trial did it the expensive way.
Thirty people with obesity took once-weekly semaglutide, escalated to 1.0 mg, and placebo, in a randomised double-blind crossover design, for 12 weeks each. Rather than asking what they ate, the researchers gave them a standardised breakfast and then unrestricted access to food, and weighed what was left.
| Meal | Effect against placebo |
|---|---|
| Lunch | 1,255 kJ less |
| Evening meal | significantly less |
| Snacks | significantly less |
| Whole day | 3,036 kJ less, a 24% reduction |
Twenty-four per cent, across every eating occasion, without anyone being told to restrict anything. Body weight fell by 5.0 kg over the 12 weeks, predominantly from fat mass.
Two other findings from the same trial matter as much as the headline.
Nausea ratings were similar between semaglutide and placebo. So the reduced eating was not people feeling too sick to eat, at least not at this dose in this group.
And resting metabolic rate, adjusted for lean body mass, did not differ between treatments. There is a persistent worry that these medicines slow the metabolism down. In this study they did not; the weight came off because less food went in.
The part people describe and rarely see quantified
Alongside eating less, the trial recorded less hunger, fewer food cravings, better control of eating, and a lower relative preference for fatty, energy-dense foods.
That last one is the interesting one, and it matches what people say. Rich food does not merely become unnecessary on a GLP-1; for many people it becomes actively unappealing. Cream, fried food, pastry and the second half of a takeaway stop being tempting rather than being resisted.
This is worth naming, because it is usually experienced as a personal transformation and it is closer to a pharmacological effect. Understanding which it is matters when the medicine stops, because the preference tends to come back with the appetite.
It also explains a common early pattern: someone finds their diet has become unintentionally low in fat, is pleased about it, and cannot work out why they feel so flat. Fat carries fat-soluble vitamins and a large share of the calories in a small volume, which on a small appetite is a feature rather than a problem.
It is not only the slow stomach
The standard explanation for all of this is delayed gastric emptying: food sits longer, you feel full sooner, you stop.
That is part of it and it is not the whole mechanism. In a randomised trial of 50 people comparing a short-acting GLP-1 with a long-acting one over 10 weeks, both reduced energy and macronutrient intake to a similar degree, and the reductions in appetite and body weight were not related to the delay in gastric emptying or to gastrointestinal side effects.
In other words, you would eat less on this medicine even if your stomach emptied normally and you felt fine. The signal is central as much as mechanical, which is also why the effect on food preference exists at all: a slow stomach has no opinion about whether you want chips.
The consequence nobody feels
Here is the arithmetic that this site exists for.
Cut total intake by roughly a quarter and, unless something changes on purpose, you cut protein by roughly a quarter too. The requirement does not move. The current expert consensus puts protein during significant weight loss at 1.2 to 2.0 g per kilogram of adjusted body weight a day, with a floor below which function suffers, specifically to protect muscle.
So a person who was managing 90 g of protein a day before starting, and is now eating 24% less of everything, is on about 68 g, against a requirement that may be 110 g or more while they are actively losing weight. That is a 40 g gap, every day, and there is nothing in the experience of it that feels wrong. You are not hungry. You are eating what you fancy. The plates look reasonable.
Weight lost in that state takes more muscle with it than it needs to.
What to do about it
Eat protein first, at every eating occasion. Not as a rule about virtue, as a queueing decision. If you are going to stop a third of the way into a meal, the third you finished should be the part that was hardest to replace.
Count occasions, not meals. On a quarter less appetite, three meals is often three chances to fall short. Four or five smaller occasions, each carrying 20 to 30 g of protein, adds up in a way two large plates you cannot finish does not.
Use the preference shift rather than fighting it. If fatty food has become unappealing, there is no point building a plan around it. Lean protein, dairy, pulses, fish and eggs tend to remain acceptable when fried and creamy things do not.
Watch for liquids doing more work than you think. When solid food is hard, milk, yoghurt drinks and soups are often the only things that go down, and they can carry real protein if chosen for it.
Do not deliberately cut fat further. It is already falling on its own. Below a certain point you lose fat-soluble vitamins and the food stops being satisfying enough to finish.
What this means when the medicine stops
If the reduced intake is pharmacological rather than a habit you built, then stopping returns you to your old intake unless you have built something in the meantime.
That is not an argument for staying on a medicine forever. It is an argument for treating the quiet period as the window in which to build the eating pattern you intend to keep: the protein-first habit, the meal structure, the shopping list. Those survive the prescription ending. The appetite suppression does not.
What to do with this
The gap between what you now eat and what your body still needs is a number, and it is the number this site exists to work out. Your protein floor comes from your weight and your dose, not from how hungry you feel today.
Sources
- Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017. PubMed
- Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 2021. PubMed
- Fujioka K. Effect of GLP-1 receptor agonist on nutrient intake: a narrative review. Nutr Clin Pract 2026. PubMed
- Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight. Diabetes Obes Metab 2021. PubMed
- Sievenpiper JL, et al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 based therapies. Obes Pillars 2026. PubMed
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity. Obesity (Silver Spring) 2025. PubMed
Medical disclaimer: Articles in the foodose research library are educational, not medical advice. Follow the instructions from your prescriber and the leaflet in your pack. See our full medical disclaimer.